Alumis Inc.
(NASDAQ:ALMS) on Monday shared topline data from its ongoing ONWARD3 long-term extension study, demonstrating that its investigational oral therapy, envudeucitinib, achieved leading skin clearance rates for patients with immune-mediated diseases.
Alumis stock initially traded higher Tuesday before pulling back and turning negative.
Exceptional Efficacy And Sustained Relief The next-generation TYK2 inhibitor, which is precision-engineered for maximum 24-hour target suppression, showed the highest reported Psoriasis Area and Severity Index (PASI) 100 response rates compared to current and experimental oral treatments.
Out of 1,509 participants who transitioned into the ONWARD3 trial from the earlier ONWARD1 and ONWARD2 studies—an impressive rollover rate of over 85%—researchers analyzed 773 individuals who underwent up to 48 weeks of continuous care.
